BioPharmSignal logoBioPharmSignal

Biotech News

Adlai Nortye Announces First Patient Enrolled in Global Phase 1 Trial of Pan-RAS (ON) Inhibitor AN9025 for Solid Tumors Harboring RAS Mutations

Adlai Nortye Ltd. (ANL)Adlai Nortye Ltd.Clinical readout

SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced that the first patient has

Related news

ANLAdlai Nortye Ltd.2026-07-16 11:00 EST

Adlai Nortye Announces First Patient Dosed in Intermittent Weekly Dosing Arm of Global Phase 1 Trial of Pan-RAS(ON) Inhibitor AN9025

ANLAdlai Nortye Ltd.2026-08-03 11:00 EST

Adlai Nortye Announces Clinical Trial Notification Submission and HREC Approval for the Phase I Clinical Trial of Pan-RAS(ON) Inhibitor ADC AN4035 in Australia

RVMDRevolution Medicines2026-06-23 12:00 EST

Revolution Medicines Begins Treating Patients in RASolute 305, a Phase 3 Clinical Trial Evaluating Zoldonrasib in Combination with Chemotherapy as a First Line Treatment for Patients with RAS G12D Metastatic Pancreatic Cancer

EXELExelixis2026-06-22 12:00 EST

Exelixis Provides Update on the Phase 3 STELLAR-303 Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Patients with Metastatic Colorectal Cancer

NBIXNeurocrine Biosciences2026-08-12 12:30 EST

Neurocrine Biosciences Announces Publication of KINECT-PRO™ Findings Demonstrating INGREZZA® (valbenazine) Capsules Improved Patient-Reported Quality of Life and Daily Functioning for People Living with Tardive Dyskinesia

RVMDRevolution Medicines2026-07-02 12:00 EST

Revolution Medicines Presents Phase 1/2 Clinical Data for Zoldonrasib Combination Regimens in Patients with RAS G12D Metastatic Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026

IDYAIDEAYA Biosciences2026-06-15 10:00 EST

IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates a Phase 1/2 Clinical Combination Study in MTAP-Deleted Pancreatic and Lung Cancers

LYELLyell Immunopharma2026-06-04 20:05 EST

Lyell Immunopharma to Present Phase 1/2 Safety and Translational Data for Ronde-Cel in Large B-Cell Lymphoma at the European Hematology Association 2026 Congress

ARGXArgenx2026-08-17 05:00 EST

argenx Announces Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis

NBIXNeurocrine Biosciences2026-08-07 12:30 EST

Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-'1968, a GLP-1/GIP/Glucagon Receptor Triple Agonist

View all latest news

Adlai Nortye Ltd.

Annovis Bio is a biotechnology company focused on neurodegenerative diseases such as Alzheimer’s and Parkinson’s. Its story centers on trying to address difficult CNS diseases with a focused molecular approach.

Recent company news

ANLAdlai Nortye Ltd.2026-08-14 11:00 EST

Adlai Nortye Ltd. Reports Unaudited First Half 2026 Financial Results and Highlights Recent Operational Progress

ANLAdlai Nortye Ltd.2026-08-03 11:00 EST

Adlai Nortye Announces Clinical Trial Notification Submission and HREC Approval for the Phase I Clinical Trial of Pan-RAS(ON) Inhibitor ADC AN4035 in Australia

ANLAdlai Nortye Ltd.2026-07-16 11:00 EST

Adlai Nortye Announces First Patient Dosed in Intermittent Weekly Dosing Arm of Global Phase 1 Trial of Pan-RAS(ON) Inhibitor AN9025

ANLAdlai Nortye Ltd.2026-07-13 11:00 EST

Adlai Nortye Expands Scientific Advisory Board with Appointment of Two Leading Medical Oncologists

ANLAdlai Nortye Ltd.2026-04-16 10:59 EST

Adlai Nortye Announces $150.0 Million Private Placement Equity Financing

Stock data

Close
13.70 USD
Market cap
745.73M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States